AtomVie Global Radiopharma Inc. ("AtomVie"), incorporated in late 2021, is a global leading CDMO for the GMP manufacturing and distribution of clinical and commercial radiopharmaceuticals and the most recent spinout from the Centre for Probe Development and Commercialization (CPDC). AtomVie offers the full range of scientific, technical, regulatory, quality, logistics and business expertise combined with a specialized infrastructure for the development of your radiopharmaceuticals from Phase 1 to the commercial marketplace. With a state-of-the art purpose-built facility that will be operational in 2024, AtomVie empowers the development of your radiotherapeutics. For more information about AtomVie, visit our website or contact: info@atomvie.com.